---
document_datetime: 2026-01-06 10:05:35
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/voriconazole-hikma-previously-voriconazole-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: voriconazole-hikma-previously-voriconazole-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3420784
conversion_datetime: 2026-01-10 11:00:16.786769
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Voriconazole Hikma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                       |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 09/12/2025                          | 19/12/2025                                  | SmPC and PL                      | To update Sections 4.3 and 4.5 of the SmPC in |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000310244   | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Sections 4.3 and 4.5 of the SmPC in order to add a   | order to add a contraindication for concomitant use with finerenone based on post-marketing data and review of the literature. The Package Leaflet was updated accordingly. In addition, changes were made to section 4.5 of the SmPC; the drug-drug interaction table is now ordered on therapeutic class and interactions affecting voriconazole are given first, followed by those interactions resulting in clinically relevant changes. The changes follow approved changes for the reference product Vfend.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|